Tresiba (insulin degludec) and Fiasp (insulin aspart), by more than 70% starting Jan. 1, 2026. Fiasp's price will be reduced by 75%, making it the same price as NovoLog (insuin aspart), while ...

Ryzodeg (insulin degludec / insulin aspart) contains the new-generation once-daily basal insulin degludec in a soluble formulation with insulin aspart. Both of these products will be available in ...

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

safety and ease of administration of the rapid-acting insulin analogue insulin aspart in comparison with human insulin (HI) in diabetes mellitus in the following categories: (a) in adults ...

Basal insulin called insulin degludec - this has a long blood sugar lowering effect. Rapid acting insulin called insulin aspart - this lowers your blood sugar soon after you inject it. Ryzodeg ...

Pharmac is seeking public feedback on a proposal to fund a new, additional type of insulin for people with diabetes from 1 May 2025. The new medicine (branded as Ryzodeg) is a combination of two other ...

Basal insulin called insulin degludec - this has a long blood sugar level lowering effect. Rapid-acting insulin called insulin aspart - this lowers your blood sugar level soon after you inject it.

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin ...

Biphasic insulin aspart 30/70 was administered once, twice or three-times daily, depending on the patient's needs; the dose was adjusted individually as required, based on the physician's decision ...

The VBP for insulin – which applies to supplies destined for hospitals in China – is expected to be implemented during the first half of 2022, according to Novo Nordisk.

insulin degludec (an ultra-long-acting insulin) and insulin aspart (a rapid-acting insulin). If the funding proposal is approved, Pharmac’s Senior Therapeutic Group Manager, Logan Heyes says the ...